These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 10098513

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effect of adenovirus-mediated overexpression of follistatin and extracellular domain of activin receptor type II on gonadotropin secretion in vitro and in vivo.
    Leal AM, Takabe K, Wang L, Donaldson CJ, MacConell LA, Bilezikjian LM, Verma IM, Vale W.
    Endocrinology; 2002 Mar; 143(3):964-9. PubMed ID: 11861519
    [Abstract] [Full Text] [Related]

  • 3. Characterization of the extracellular ligand-binding domain of the type II activin receptor.
    Greenwald J, Le V, Corrigan A, Fischer W, Komives E, Vale W, Choe S.
    Biochemistry; 1998 Nov 24; 37(47):16711-8. PubMed ID: 9843440
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Inhibin antagonizes inhibition of liver cell growth by activin by a dominant-negative mechanism.
    Xu J, McKeehan K, Matsuzaki K, McKeehan WL.
    J Biol Chem; 1995 Mar 17; 270(11):6308-13. PubMed ID: 7890768
    [Abstract] [Full Text] [Related]

  • 7. Identification of a binding site on the type II activin receptor for activin and inhibin.
    Gray PC, Greenwald J, Blount AL, Kunitake KS, Donaldson CJ, Choe S, Vale W.
    J Biol Chem; 2000 Feb 04; 275(5):3206-12. PubMed ID: 10652306
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Activin signaling through activin receptor type II causes the cachexia-like symptoms in inhibin-deficient mice.
    Coerver KA, Woodruff TK, Finegold MJ, Mather J, Bradley A, Matzuk MM.
    Mol Endocrinol; 1996 May 04; 10(5):534-43. PubMed ID: 8732684
    [Abstract] [Full Text] [Related]

  • 11. Monomeric activin A retains high receptor binding affinity but exhibits low biological activity.
    Hüsken-Hindi P, Tsuchida K, Park M, Corrigan AZ, Vaughan JM, Vale WW, Fischer WH.
    J Biol Chem; 1994 Jul 29; 269(30):19380-4. PubMed ID: 8034704
    [Abstract] [Full Text] [Related]

  • 12. Activin and inhibin have antagonistic effects on ligand-dependent heteromerization of the type I and type II activin receptors and human erythroid differentiation.
    Lebrun JJ, Vale WW.
    Mol Cell Biol; 1997 Mar 29; 17(3):1682-91. PubMed ID: 9032295
    [Abstract] [Full Text] [Related]

  • 13. Concomitant over-expression of activin/inhibin beta subunits and their receptors in human pancreatic cancer.
    Kleeff J, Ishiwata T, Friess H, Büchler MW, Korc M.
    Int J Cancer; 1998 Sep 11; 77(6):860-8. PubMed ID: 9714055
    [Abstract] [Full Text] [Related]

  • 14. Tumor-specific expression and alternate splicing of messenger ribonucleic acid encoding activin/transforming growth factor-beta receptors in human pituitary adenomas.
    Alexander JM, Bikkal HA, Zervas NT, Laws ER, Klibanski A.
    J Clin Endocrinol Metab; 1996 Feb 11; 81(2):783-90. PubMed ID: 8636304
    [Abstract] [Full Text] [Related]

  • 15. Three-finger toxin fold for the extracellular ligand-binding domain of the type II activin receptor serine kinase.
    Greenwald J, Fischer WH, Vale WW, Choe S.
    Nat Struct Biol; 1999 Jan 11; 6(1):18-22. PubMed ID: 9886286
    [Abstract] [Full Text] [Related]

  • 16. Rodent adrenocortical cells display high affinity binding sites and proteins for inhibin A, and express components required for autocrine signalling by activins and bone morphogenetic proteins.
    Farnworth PG, Wang Y, Leembruggen P, Ooi GT, Harrison C, Robertson DM, Findlay JK.
    J Endocrinol; 2006 Mar 11; 188(3):451-65. PubMed ID: 16522726
    [Abstract] [Full Text] [Related]

  • 17. Dynamic regulation of pituitary follistatin messenger ribonucleic acids during the rat estrous cycle.
    Halvorson LM, Weiss J, Bauer-Dantoin AC, Jameson JL.
    Endocrinology; 1994 Mar 11; 134(3):1247-53. PubMed ID: 8119165
    [Abstract] [Full Text] [Related]

  • 18. Prevention of cachexia-like syndrome development and reduction of tumor progression in inhibin-deficient mice following administration of a chimeric activin receptor type II-murine Fc protein.
    Li Q, Kumar R, Underwood K, O'Connor AE, Loveland KL, Seehra JS, Matzuk MM.
    Mol Hum Reprod; 2007 Sep 11; 13(9):675-83. PubMed ID: 17704537
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Stimulation of activin receptor II signaling pathways inhibits differentiation of multiple gastric epithelial lineages.
    Li Q, Karam SM, Coerver KA, Matzuk MM, Gordon JI.
    Mol Endocrinol; 1998 Feb 11; 12(2):181-92. PubMed ID: 9482661
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.